FDA gets to grips with pharmacogenomics:
This article was originally published in Clinica
The US FDA wants to meet with officials from industry to learn about the demands involved in developing pharmacogenomic products. The agency will use the comments to help shape an upcoming guidance document on the topic. The day-long meeting at the Marriott Crystal Gateway Hotel in Arlington County, Virginia, will take place on July 29 from 8 am. Register by July 26, and submit comments by August 30. For more information, contact the meeting's co-sponsor, the Drug Information Association at email: firstname.lastname@example.org
You may also be interested in...
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.